Chief Executive Officer
Dr. Velleca joined G1 as Chief Executive Officer in 2014. Previously, he was at CGI Pharmaceuticals, where he guided the company from its inception through its establishment as a drug discovery company that brought multiple drug candidates into clinical trials. After Gilead Sciences acquired CGI, Dr. Velleca served as a senior advisor to Gilead in R&D Strategy and Corporate Development. Earlier in his career, Dr. Velleca was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.
Dr. Velleca earned an M.D. and Ph.D. from Washington University in St. Louis, and a B.S. from Yale University. He has served on the boards of directors and scientific advisory boards of several biotechnology companies, including Intellikine, an oncology therapeutics company acquired by Takeda in 2011. He most recently served as Executive Vice President at the Leukemia & Lymphoma Society.
Chief Medical Officer and Senior Vice President, R&D
Dr. Malik joined G1 in 2014. Most recently, he served as Chief Medical Officer and management board member at Agennix AG, where he was responsible for research and development. Prior to Agennix AG, he served as Chief Medical Officer at Adherex Technologies, where he directed the company's global regulatory strategy and clinical development programs. Dr. Malik also served in oncology clinical development positions at EMD Pharmaceuticals and Bristol-Myers Squibb. Dr. Malik currently serves on the Board of Directors of Meryx, Inc.
Dr. Malik received his MD from the University of Sheffield Medical School in the UK. He completed his residency at Duke University Medical Center and fellowships at the Children's Hospital of Philadelphia and Duke University Medical Center. During his academic career, he was an assistant professor at the University of Virginia, where he conducted basic science and clinical research in addition to patient care and teaching.
Senior Vice President, Development Operations
Mr. Murdock joined G1 as Senior Vice President of Development Operations in 2017. Most recently he served as Vice President and Global Head of the Oncology Center of Excellence at QuintilesIMS, where he focused on developing insights and innovations that helped improve the probability of success for QuintilesIMS’ oncology customer development projects and programs.
Mr. Murdock has more than 20 years of work experience as a successful senior executive in the medical research industry, specializing in oncology, multiple sclerosis and other autoimmune diseases. He is experienced at establishing operational excellence within culturally diverse environments with a successful track record of executing operational, clinical development, and commercial plans. Prior to QuintilesIMS, Mr. Murdock also held senior positions at Ergomed, Genzyme/Sanofi, ILEX Oncology, and US Oncology.
Mr. Murdock earned his M.S. in biology and a B.S. in microbiology from the University of Texas, Arlington.
Chief Financial Officer and Senior Vice President, Corporate Development
Mr. Phillips joined G1 as Chief Financial Officer and Senior Vice President, Corporate Development in 2017. Previously, he served as Chief Financial Officer of the publicly traded biotech companies Novavax, Inc., and Micromet, Inc., an oncology company acquired by Amgen in 2012. Earlier in his career, he worked for 20 years in the institutional public and private biotechnology investment industries.
Mr. Phillips brings a long history of biotech-specific finance and business experience to G1, including financial reporting, financial planning and analysis, financing strategy, investor relations, as well as, corporate development activities, strategic partnering and M&A.
Mr. Phillips received a B.A. in economics from the University of Colorado, Boulder.
Chief Scientific Officer
Dr. Strum joined G1 as its first employee and founding Chief Scientific Officer in 2009. He was instrumental in building G1's kinase drug discovery platform and in recruiting, leading and managing the R&D team. Prior to G1, Dr. Strum led drug discovery programs in cancer and metabolic diseases at GlaxoSmithKline, where he brought multiple drug candidates into clinical development. He played a key role in establishing and driving genomics research at GlaxoSmithKline through the creation and management of an international gene expression department that included a human tissue repository and a human adipose-derived stem cell laboratory.
Dr. Strum obtained his PhD in biochemistry from Wake Forest University and did postdoctoral work with Dr. Bob Bell in molecular cancer biology at Duke University. His broad multidisciplinary experience in research and development includes being an author on more than 40 scientific papers and three book chapters, and an inventor / co-inventor on 18 patents.
Vice President, Clinical Development and Product Team Leader – Trilaciclib
Dr. Morris joined G1 as Vice President, Clinical Development, serving as Product Team Leader for trilaciclib, in April 2017. Prior to joining G1, Dr. Morris was Senior Director, Clinical Development, Immuno-Oncology at MedImmune, a member of the Astra Zeneca Group. At MedImmune, she was instrumental in the approval of durvalumab in bladder cancer, the transition of the durvalumab/tremelimumab combination in hepatocellular carcinoma to late stage development and the FTIH evaluation of the novel TLR 7/8 agonist MEDI9197. Prior to joining MedImmune, Dr. Morris rose to Senior Clinical Director at GlaxoSmithKline, where she was the physician lead for early phase development of the AKT and pan-PI3K inhibitor programs, and participated in the FTIH dose-escalation evaluation of the MEK inhibitor, trametinib which was subsequently approved for use in BRAF-mutant metastatic melanoma.
Dr. Morris earned her M.D. and Ph.D. from Case Western Reserve University in Cleveland, OH, and completed her medical residency and oncology fellowship at the University of North Carolina, Chapel Hill, N.C. During her oncology fellowship, she participated in the Early Drug Development Fellowship in partnership with GlaxoSmithKline.
Vice President, Clinical Development and Product Team Leader – G1T38, G1T48
Dr. Beelen joined G1 as Senior Director, Clinical Development, serving as Product Team Leader for G1T38, in April 2016. He has since taken on the additional responsibility of Product Team Leader for G1T48, and was named Vice President, Clinical Development. Prior to joining G1, Dr. Beelen served as Senior Oncology Medical Director at Quintiles.
Dr. Beelen has more than 15 years of experience in pharmaceutical drug development, primarily in oncology therapeutics. Earlier in his career, he held roles of increasing responsibility including Vice President of Clinical Research at Myrexis and Director of Clinical Pharmacology and Discovery Medicine at GlaxoSmithKline, where he was responsible for the clinical pharmacology development program of lapatinib (TYKERB), including early phase combination chemotherapy studies.
Dr. Beelen earned his MD from SUNY Upstate Medical University in Syracuse, N.Y., and completed an internal medicine residency and clinical pharmacology fellowship at Dartmouth Hitchcock Medical Center in Lebanon, N.H. During his fellowship, Dr. Beelen was a sub-investigator for several early phase oncology clinical trials.
Vice President, Global Regulatory Affairs
Ms. Lovejoy joined G1 as Vice President, Global Regulatory Affairs in 2017. She has nearly two decades of experience in global drug development, specializing in oncology. Most recently, she led global regulatory strategy as Senior Vice President, Global Regulatory Affairs and Head of Quality at Sierra Oncology. Earlier in her career, Ms. Lovejoy held roles of increasing responsibility at Endocyte, including as Global Vice President of Regulatory Affairs, and at Genentech, where she served as regulatory lead on the AVASTIN® team. Ms. Lovejoy has led cross-functional team activities from Investigational New Drug applications, implementation and conduct of global clinical trials, and successful negotiations with the U.S. Food and Drug Administration and European Medicines Agency regarding complex pivotal trials, to the submission and review of marketing applications.
Ms. Lovejoy has an M.S. in regulatory affairs from San Diego State University, and a B.S. in organizational behavior from the University of San Francisco.
Vice President, Technical Operations
Mr. Smith began working with G1 in 2013 as a CMC consultant and joined the company as Vice President, Technical Operations in April 2015. Previously, Mr. Smith held Vice President positions at the biopharmaceutical companies Serenex and Viamet, and served as Vice President, Development at Fulcrum Pharma Developments, a global consulting company. Earlier in his career, Mr. Smith served in positions at large, medium and small pharma companies including Burroughs-Wellcome, Glaxo-Wellcome, UCB Pharma and Triangle Pharmaceuticals. Mr. Smith’s experience encompasses all aspects of chemistry, manufacturing and controls, drug substance, drug product and CMC regulatory affairs. He has contributed to the New Drug Applications for Zyban® SR Tablets, Valtrex® Tablets, and Emtriva® Capsules and Oral Solution.
Mr. Smith holds an M.S. in pharmaceutical chemistry from Lehigh University, and a B.S. in chemistry from the University of North Carolina, Chapel Hill..
Vice President, Finance and Administration
Ms. Moses began working with G1 in 2012 as a financial consultant and joined the company as Vice President, Finance and Administration in March 2015. Previously, Ms. Moses was a partner at the firm of Rankin McKenzie, LLC, a professional finance and accounting services firm, where she provided financial and accounting services to private, venture-backed companies. Prior to joining Rankin McKenzie, Ms. Moses was a senior manager in the tax services group of Deloitte LLP, where she served clients ranging from small, emerging growth companies to large publicly traded corporations.
Ms. Moses received her B.S. in accounting from Pennsylvania State University and is a certified public accountant.
Vice President, Quality and Compliance
Mr. Jensen joined G1 as Vice President, Quality and Compliance in 2018. Prior to G1, Mr. Jensen established and oversaw quality management systems at two other biotech companies in the Research Triangle Park area: Heat Biologics and Precision BioSciences. Before moving into the biotech space, he spent more than 12 years in Quality functions of increasing responsibility at INC Research (now Syneos Health) and PPD. At PPD, Mr. Jensen was Executive Director of Quality Risk Management and oversaw global audit and inspection programs, the corporate CAPA and vendor management systems, and quality governance initiatives for strategic partnerships. Mr. Jensen also spent several years as a U.S. Food and Drug Administration (FDA) field investigator.
Mr. Jensen earned his MBA at the University of North Carolina Wilmington and holds a B.S. in Biology from the University of Utah.
Head of Human Resources
Ms. Zellner began working with G1 in 2016 as a human resources consultant and joined the company as Head of Human Resources in January 2018. Ms. Zellner brings more than 15 years of experience in human resources management in the biopharmaceutical industry to G1, working with emerging organizations to provide leadership direction and managing human resources strategy and initiatives. Earlier in her career, Ms. Zellner served in management roles at Inspire Pharmaceuticals and Aerocrine, Inc., specializing in human resources strategy, talent acquisition, employee relations, benefits administration, employee engagement, performance management, training and coaching.
Ms. Zellner holds a certification in Professional Human Resources and is a Society for Human Resources Management certified professional and a Certified Professional Coach.
Head of Investor Relations / Public Relations
Mr. Macdonald joined G1 as Head of Investor Relations / Public Relations in 2018. Previously, he served as Executive Director, Corporate Communications at Acorda Therapeutics, where he developed and implemented strategic corporate communications initiatives and investor relations programming. Earlier in his career, he held various corporate and brand communications positions at Bristol-Myers Squibb, as well as working in the healthcare practices of several international public relations agencies.
With more than 20 years of healthcare communications, Mr. Macdonald has experience supporting enterprises ranging from multinational pharmaceutical companies to emerging biopharma start-ups. He has led initiatives including investor outreach, corporate reputation and crisis management, media relations, product launch support, employee communications, and advocacy relations.
Mr. Macdonald received a B.A. in English and Journalism from Washington & Lee University in Lexington, Virginia.